Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Albert Hu maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $50 to $60.
Citigroup analyst Albert Hu maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $50 to $60.